Creating the next generation of therapeutics for neurodegenerative disorders.LEARN MORE
We utilize data and machine learning to identify novel drivers of disease and then design molecules for those diseases in silico.
We are a cloud based high performance computing company. We conduct data analytics, design drugs, and screen molecules in silico.
Our proprietary platform designs small molecule therapeutics to help improve neurological functions in patients.
We are seeing an inflection point in computational biology where synergies between pharma customers and startups are fast-tracking innovations through the clinic at an unprecedented rate.
Over the last two years, we have seen over $2 billion in pharma bio bucks being spent on non-dilutive R&D capital for computational bio startups to help uncover new therapeutics - especially as their assets come off patent.